Hanmi Pharmaceutical, which attracted wide attention by launching the first generic version of the prostate cancer treatment Zytiga last year, set out to target the market again by quickly developing a combination drug.

On the 14th, the Ministry of Food and Drug Safety approved Hanmi Pharmaceutical's Abiteron Duo Tab 500/2.5mg.

The product is a combination drug that combines abiraterone and prednisolone.

The original drug is Janssen’s ‘Zytiga Tab 500mg (abiraterone acetate).’ Hanmi Pharmaceutical received approval for the first generic version of Zytiga, ‘Abiteron Tab 500mg,’ last year, and released the drug at a more economical price than the original in Oc